Evidence map›Paper›PMID 42335172›Full record

ArticlePLoS medicine2026

Multi-omics biomarkers of endothelial dysregulation preceding chronic lung allograft dysfunction: A prospective cohort study.

Giulia Iacono, Christina Begka, Bailey Cardwell, Carmel Daunt, Roxanne Chatzis, Celine Pattaroni, Alana Butler, Matthew Macowan, Bronwyn Levvey, Gregory I Snell and 2 more

Abstract read
In one paragraph

Article in PLoS medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Giulia IaconoDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia.ORCID https://orcid.org/0000-0002-1527-0754
Christina BegkaDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia.
Bailey CardwellDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia.ORCID https://orcid.org/0000-0003-4686-4210
Carmel DauntDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia.
Roxanne ChatzisDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia.
Celine PattaroniDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia.
Alana ButlerDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia.
Matthew MacowanDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia.ORCID https://orcid.org/0000-0001-7721-1349
Bronwyn LevveyLung Transplant Service, Department of Respiratory Medicine, Alfred Hospital, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-1954-4249
Gregory I SnellLung Transplant Service, Department of Respiratory Medicine, Alfred Hospital, Melbourne, Victoria, Australia.
Glen P WestallDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia.
Benjamin J MarslandDepartment of Immunology, School of Translational Medicine, Monash University, Melbourne, Australia.ORCID https://orcid.org/0000-0003-1457-3160

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong-term survival of lung transplant recipients remains limited by chronic lung allograft dysfunction (CLAD). CLAD is only diagnosed following a persistent and substantial decline in lung function, after which irreversible damage to the lungs has occurred, limiting opportunities to effectively intervene at an early stage. There is a critical need for earlier detection prior to its clinical manifestation. The immunological drivers of CLAD remain unclear, limiting the development of predictive biomarkers and new therapies. METHODS AND

findingsIn this hypothesis-generating, prospective cohort study, we profiled the microbial, metabolic, lipidomic, and gene expression dynamics of longitudinally collected broncho-alveolar lavages (BALs) from 56 CLAD-free lung transplant recipients up to 30 months post-transplant, and compared BALs from 13 CLAD-free patients to BALs from 13 patients who developed CLAD. In CLAD-free patients, the first 6 months post-transplant were hallmarked by diminished microbial diversity and increased abundance of Staphylococcus and Candida, coupled with upregulated innate and adaptive immune responses, and elevated nitric oxide metabolism (FDR < 0.05). This was superseded by homeostatic tissue repair and by the reactivation of T-cell genes such as CD3, GZMA, IL2RB, CD28, CD40LG, and LCK, after tapering of maintenance immunosuppression (FDR < 0.05). In patients who developed CLAD, disease onset was preceded by the increased abundance of sphingolipids and the upregulation of glycocalyx and immune cell recruitment genes such as HAPLN3, HS3ST3B1, SULF2, CHST2, CSGALNACT1, CXCR1, CSF3R, SELL, CXCL2, and CEACAM1 (FDR < 0.05), suggesting increased vascular dysfunction and immune cell graft infiltration prior to CLAD onset. Scoring against a publicly available lung single-cell dataset showed our bulk gene transcriptomics signature to be expressed by monocytes, endothelial, and T cells. In contrast to CLAD-free patients, this signature persisted after 1.5 months post-transplant and increased in intensity upon the start of lung function decline. Multi-omics integration highlighted sphingolipid molecules and genes involved in immune cell recruitment and endothelial function as candidate biomarkers associated with the onset of CLAD. This study is limited by its small sample size.

conclusionsWe have identified immunological processes, metabolites, lipids, and genes associated with the onset of CLAD. Our findings are to be considered associative and not aimed at establishing causality. Future studies employing a targeted approach in independent validation cohorts, using, for example, quantitative polymerase chain reaction (PCR) and targeted mass-spectrometry, will be required to confirm these findings.

Indexed as

LungLung TransplantationPrimary Graft DysfunctionAdultAllograftsBiomarkersBronchoalveolar Lavage FluidChronic DiseaseFemaleHumansMaleMiddle AgedMultiomicsProspective StudiesBiomarkers

Identifiers

PMID42335172
PMCPMC13289948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.